サイクロオキシゲナーゼ抑制と心血管疾患のリスク
Elliott M Antman1, David DeMets, Joseph Loscalzo
1Cardiovascular Division, Department of Medicine, Brigham & Women's Hospital, 75 Francis St, Boston, MA 02115, USA. eantman@rics.bwh.harvard.edu
No abstract available in PubMed .
さらに関連する動画
08:41Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues
Published on: June 3, 2019
07:40Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
関連する概念動画
Inhibition of Cdk Activity
Inhibition of CDK Activity
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease I: Introduction
Coronary Artery Disease II: Pathophysiology
Hypertension II: Pathophysiology
